| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1010596045 |
| P356 | DOI | 10.1186/1471-2164-9-239 |
| P932 | PMC publication ID | 2423197 |
| P698 | PubMed publication ID | 18498629 |
| P5875 | ResearchGate publication ID | 5350835 |
| P50 | author | Marco A. Pierotti | Q30668534 |
| Benjamin Haibe-Kains | Q38639014 | ||
| Christine Desmedt | Q39032761 | ||
| Sherene Loi | Q42315566 | ||
| Maria Grazia Daidone | Q42425282 | ||
| Gianluca Bontempi | Q58032645 | ||
| Mauro Delorenzi | Q86447104 | ||
| Pratyaksha Wirapati | Q95832208 | ||
| Christos Sotiriou | Q96239849 | ||
| John A Foekens | Q114340561 | ||
| Françoise Lallemand | Q114737686 | ||
| Cheryl Gillet | Q114737687 | ||
| P2093 | author name string | Paul Ellis | |
| James F Reid | |||
| Martine J Piccart | |||
| Els Mjj Berns | |||
| Maurice Phm Jansen | |||
| Kenneth Ryder | |||
| Andrew M Tutt | |||
| P2860 | cites work | Semi-supervised methods to predict patient survival from gene expression data | Q24804682 |
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| A comparison of normalization methods for high density oligonucleotide array data based on variance and bias | Q27860710 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| ''R"--project for statistical computing | Q29618640 | ||
| Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis | Q30004190 | ||
| CleanEx: a database of heterogeneous gene expression data based on a consistent gene nomenclature | Q30886384 | ||
| Limits of predictive models using microarray data for breast cancer clinical treatment outcome | Q30992101 | ||
| Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling | Q33211344 | ||
| Breast cancer classification and prognosis based on gene expression profiles from a population-based study | Q35918291 | ||
| Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers | Q40310725 | ||
| A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen | Q40546564 | ||
| Slit protein-mediated inhibition of CXCR4-induced chemotactic and chemoinvasive signaling pathways in breast cancer cells | Q40612882 | ||
| RECK is a target of Epstein–Barr virus latent membrane protein 1 | Q40616852 | ||
| Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade | Q42510471 | ||
| Outcome signature genes in breast cancer: is there a unique set? | Q42633433 | ||
| Tamoxifen treatment failure in cancer and the nonlinear dynamics of TGFbeta | Q44921853 | ||
| Reliable gene signatures for microarray classification: assessment of stability and performance | Q50715191 | ||
| Prediction of cancer outcome with microarrays: a multiple random validation strategy | Q62785637 | ||
| Averaged gene expressions for regression | Q83337158 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| tamoxifen | Q412178 | ||
| estrogen-receptor positive breast cancer | Q18553636 | ||
| P304 | page(s) | 239 | |
| P577 | publication date | 2008-05-22 | |
| P1433 | published in | BMC Genomics | Q15765854 |
| P1476 | title | Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen | |
| P478 | volume | 9 |
| Q28730572 | 'Omic approaches to preventing or managing metastatic breast cancer |
| Q37741425 | A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy |
| Q52657794 | A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. |
| Q30587056 | A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer |
| Q51247871 | A discrimination index for selecting markers of tumor growth dynamic across multiple cancer studies with a cure fraction. |
| Q38980243 | A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers |
| Q33861620 | A fuzzy gene expression-based computational approach improves breast cancer prognostication |
| Q35566213 | A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance |
| Q35501973 | A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer |
| Q46799300 | A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer |
| Q35683556 | A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis |
| Q53420712 | A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity. |
| Q44615442 | A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation |
| Q35684445 | A role for estrogen receptor phosphorylation in the resistance to tamoxifen |
| Q33575180 | A semi-parametric Bayesian model for unsupervised differential co-expression analysis |
| Q35769036 | A three-gene model to robustly identify breast cancer molecular subtypes |
| Q33432300 | A transcriptional sketch of a primary human breast cancer by 454 deep sequencing |
| Q33407768 | A voting approach to identify a small number of highly predictive genes using multiple classifiers |
| Q37209259 | Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer |
| Q36445441 | Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer |
| Q37685442 | Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells |
| Q28728499 | Amplified Loci on Chromosomes 8 and 17 Predict Early Relapse in ER-Positive Breast Cancers |
| Q33618520 | An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer |
| Q33971409 | An Integrated Bioinformatics Approach Identifies Elevated Cyclin E2 Expression and E2F Activity as Distinct Features of Tamoxifen Resistant Breast Tumors |
| Q42776111 | An Integrative Pathway-based Clinical-genomic Model for Cancer Survival Prediction |
| Q34491930 | An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis |
| Q58599063 | An assessment of prognostic immunity markers in breast cancer |
| Q51663878 | An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer. |
| Q42490628 | Anacardic Acid, Salicylic Acid, and Oleic Acid Differentially Alter Cellular Bioenergetic Function in Breast Cancer Cells |
| Q34592610 | Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis |
| Q33689986 | Analyzing the regulation of metabolic pathways in human breast cancer |
| Q41786087 | Annotation enrichment analysis: an alternative method for evaluating the functional properties of gene sets |
| Q36713946 | Antiestrogen Resistance and the Application of Systems Biology |
| Q26829025 | Arylamine N-acetyltransferase 1: a novel drug target in cancer development |
| Q24653339 | Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer |
| Q34125826 | Association of HADHA expression with the risk of breast cancer: targeted subset analysis and meta-analysis of microarray data |
| Q37080948 | BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. |
| Q37585095 | Biological determinants of endocrine resistance in breast cancer |
| Q38076082 | Breast cancer biomarker measurements and standards |
| Q83457870 | Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib |
| Q35683548 | Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications |
| Q37689788 | BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome |
| Q33788520 | Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. |
| Q24633702 | CD36 Repression Activates a Multicellular Stromal Program Shared by High Mammographic Density and Tumor Tissues |
| Q37149776 | Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis |
| Q55269061 | Collaborative Management of Patients With Estrogen Receptor-Positive Breast Cancer. |
| Q38422177 | Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial |
| Q36038766 | Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer |
| Q33586734 | Comparison of scores for bimodality of gene expression distributions and genome-wide evaluation of the prognostic relevance of high-scoring genes. |
| Q88792280 | Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers |
| Q47145727 | Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer |
| Q36337751 | Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. |
| Q90223181 | Concordance between Immunohistochemistry and Microarray Gene Expression Profiling for Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Statuses in Breast Cancer Patients in Lebanon |
| Q36253768 | Contextual Refinement of Regulatory Targets Reveals Effects on Breast Cancer Prognosis of the Regulome |
| Q42439587 | Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis |
| Q35008633 | Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody |
| Q36245357 | Crk adaptor proteins act as key signaling integrators for breast tumorigenesis |
| Q64122533 | Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER breast cancer |
| Q34117601 | DEAD-box helicase DP103 defines metastatic potential of human breast cancers |
| Q34154147 | Deconstructing the molecular portraits of breast cancer |
| Q41136265 | Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease |
| Q45077709 | Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients. |
| Q34356351 | Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data |
| Q90643299 | Differential impact of classical and non-canonical NF-κB pathway-related gene expression on the survival of breast cancer patients |
| Q46086451 | Disclosure of individual research results in clinico-genomic trials: challenges, classification and criteria for decision-making: Table 1 |
| Q28273187 | Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome |
| Q31141334 | Double-edged role of G protein-coupled estrogen receptor 1 in breast cancer prognosis: an analysis of 167 breast cancer samples and online data sets |
| Q34506613 | Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. |
| Q34048134 | Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. |
| Q92342048 | Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups |
| Q34093736 | Dysregulation of the mevalonate pathway promotes transformation |
| Q35000629 | E2F4 regulatory program predicts patient survival prognosis in breast cancer |
| Q36544743 | E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter |
| Q36490260 | EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination |
| Q37589139 | EI24 regulates epithelial-to-mesenchymal transition and tumor progression by suppressing TRAF2-mediated NF-κB activity |
| Q37688408 | EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer |
| Q35620279 | ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer |
| Q37302065 | ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization. |
| Q21563388 | ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1 |
| Q37209400 | Effects of sample size on robustness and prediction accuracy of a prognostic gene signature |
| Q38651954 | Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia |
| Q33669571 | Enumerating the gene sets in breast cancer, a "direct" alternative to hierarchical clustering |
| Q34895090 | Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer |
| Q47829743 | Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy |
| Q36397942 | Estrogen receptor prevents p53-dependent apoptosis in breast cancer |
| Q89480730 | Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy |
| Q39236899 | Estrogens regulate life and death in mitochondria |
| Q35503492 | Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value |
| Q41135362 | Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting. |
| Q36277279 | Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation |
| Q44330684 | Feature extraction via composite scoring and voting in breast cancer |
| Q39323439 | Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen |
| Q35238047 | G-DOC: a systems medicine platform for personalized oncology |
| Q91804665 | GENT2: an updated gene expression database for normal and tumor tissues |
| Q21560759 | GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in Breast Cancer |
| Q35133195 | Gasdermin-B promotes invasion and metastasis in breast cancer cells |
| Q37958156 | Gene expression profiling in breast cancer: classification, prognostication, and prediction |
| Q34559124 | Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study |
| Q37327550 | Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis |
| Q35849104 | Gene-expression signature functional annotation of breast cancer tumours in function of age |
| Q35832016 | Genetic characterization of breast cancer and implications for clinical management |
| Q48674329 | Genome-wide expression profiling as a clinical tool: are we there yet? |
| Q35779181 | Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen |
| Q39588977 | Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. |
| Q92513262 | Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses |
| Q38965383 | High NR2F2 transcript level is associated with increased survival and its expression inhibits TGF-β-dependent epithelial-mesenchymal transition in breast cancer |
| Q36134749 | Highly informative marker sets consisting of genes with low individual degree of differential expression |
| Q33813981 | Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. |
| Q35149689 | Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype |
| Q47129006 | Identification and characterization of a metastatic suppressor BRMS1L as a target gene of p53. |
| Q64061927 | Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study |
| Q34171827 | Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer |
| Q36559266 | Identifying protein interaction subnetworks by a bagging Markov random field-based method. |
| Q36629870 | In Silico Discovery of Mitosis Regulation Networks Associated with Early Distant Metastases in Estrogen Receptor Positive Breast Cancers |
| Q33727273 | Increased macroH2A1.1 expression correlates with poor survival of triple-negative breast cancer patients |
| Q36117179 | Independent and functional validation of a multi-tumour-type proliferation signature |
| Q34129423 | Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype |
| Q45011513 | Isoflavones in soy flour diet have different effects on whole-genome expression patterns than purified isoflavone mix in human MCF-7 breast tumors in ovariectomized athymic nude mice |
| Q34069945 | Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance |
| Q27309896 | Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE. |
| Q42739835 | Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene |
| Q37437363 | Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer |
| Q37130478 | MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment |
| Q33854993 | Meta-analysis of gene expression microarrays with missing replicates |
| Q34904277 | Metabotropic Glutamate Receptor 1 Expression and Its Polymorphic Variants Associate with Breast Cancer Phenotypes |
| Q35686077 | Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics |
| Q42414285 | Microarray data analysis in neoadjuvant biomarker studies in estrogen receptor-positive breast cancer |
| Q33974923 | Microarray-Based Oncogenic Pathway Profiling in Advanced Serous Papillary Ovarian Carcinoma |
| Q37356684 | Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? |
| Q35558070 | Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction |
| Q36363626 | Microenvironment and endocrine resistance in breast cancer: Friend or foe? |
| Q37078095 | Module-based breast cancer classification |
| Q34374191 | Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes |
| Q45265273 | Multivariate gene-set testing based on graphical models |
| Q64259213 | Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research |
| Q36214336 | Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen |
| Q56515226 | Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer |
| Q92541751 | OSbrca: A Web Server for Breast Cancer Prognostic Biomarker Investigation With Massive Data From Tens of Cohorts |
| Q34051213 | Overexpression of POLQ confers a poor prognosis in early breast cancer patients |
| Q52877983 | Overexpression of Ran GTPase Components Regulating Nuclear Export, but not Mitotic Spindle Assembly, Marks Chromosome Instability and Poor Prognosis in Breast Cancer |
| Q36147185 | PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer |
| Q34085622 | PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer. |
| Q35744180 | PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGFβ Responses in Breast Cancer |
| Q33933172 | PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer |
| Q34346725 | Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance |
| Q83638671 | Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis |
| Q37855305 | Personalized Medicine: The Road Ahead |
| Q33586739 | Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context |
| Q35631178 | Predictive networks: a flexible, open source, web application for integration and analysis of human gene networks |
| Q104617805 | Pregnancy-specific glycoprotein 9 acts as both a transcriptional target and a regulator of the canonical TGF-β/Smad signaling to drive breast cancer progression |
| Q33434943 | PrognoScan: a new database for meta-analysis of the prognostic value of genes |
| Q36629530 | Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas |
| Q57809308 | Prognostic values of F-box members in breast cancer: an online database analysis and literature review |
| Q37690351 | Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers |
| Q45817225 | Quantification of ER/PR expression in ovarian low-grade serous carcinoma |
| Q33917439 | Quantifying differential gene connectivity between disease states for objective identification of disease-relevant genes. |
| Q50917397 | ROCK: a resource for integrative breast cancer data analysis. |
| Q51109186 | RRHGE: a novel approach to classify the estrogen receptor based breast cancer subtypes. |
| Q42099513 | Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. |
| Q42446501 | Raf kinase inhibitory protein role in the molecular subtyping of breast cancer |
| Q28114915 | Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer |
| Q51049666 | Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures. |
| Q91586214 | Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer |
| Q55000405 | Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells. |
| Q33637070 | Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer |
| Q36936190 | SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer |
| Q33534511 | SplicerAV: a tool for mining microarray expression data for changes in RNA processing |
| Q54179268 | Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes. |
| Q34644894 | Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer |
| Q35159023 | Systematic identification of signaling pathways with potential to confer anticancer drug resistance. |
| Q28115071 | TMEM33: a new stress-inducible endoplasmic reticulum transmembrane protein and modulator of the unfolded protein response signaling |
| Q37136305 | TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer |
| Q38253588 | TRAF4 mediates activation of TGF-β signaling and is a biomarker for oncogenesis in breast cancer |
| Q38859693 | Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors |
| Q48578774 | Tamoxifen resistance in breast cancer is regulated by the EZH2-ERα-GREB1 transcriptional axis. |
| Q36689052 | Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer |
| Q39411427 | Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells |
| Q28069626 | Targeting the RB-E2F pathway in breast cancer |
| Q37524275 | Taxonomy of breast cancer based on normal cell phenotype predicts outcome. |
| Q24296824 | The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells |
| Q39148977 | The ShcA PTB Domain Functions as a Biological Sensor of Phosphotyrosine Signaling during Breast Cancer Progression |
| Q92799863 | The Tumor Microenvironment as a Regulator of Endocrine Resistance in Breast Cancer |
| Q36089048 | The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures |
| Q38321134 | The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells. |
| Q34745747 | The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis |
| Q50048638 | Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. |
| Q33570282 | Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis |
| Q33827037 | VAV3 mediates resistance to breast cancer endocrine therapy. |
| Q38750948 | ZNF503/Zpo2 drives aggressive breast cancer progression by down-regulation of GATA3 expression |
| Q34869169 | c-Jun N-terminal Kinase 2 (JNK2) Enhances Cell Migration through Epidermal Growth Factor Substrate 8 (EPS8) |
| Q33640925 | mAPC-GibbsOS: an integrated approach for robust identification of gene regulatory networks. |
| Q61805409 | pAKT pathway activation is associated with mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation |
| Q39617697 | β-catenin-independent WNT signaling in basal-like breast cancer and brain metastasis |
Search more.